Open Data and Materials

 

A Public Option for Clinical Trials? Lessons from Convalescent Plasma

The case of clinical trials for convalescent plasma during COVID-19 illustrates important lessons for realizing public sector approaches to biomedical research and development. These lessons, centering on mission, transparency, and spillover effects, …

Advocating for Generalizability: Accepting Inherent Variability in Translation of Animal Research Outcomes

Advancing scientific discovery requires investigators to embrace research practices that increase transparency and disclosure about materials, methods, and outcomes. Several research advocacy and funding organizations have produced guidelines and …

Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research

Real-world evidence (RWE) studies are increasingly used to inform policy and clinical decisions. However, there remain concerns about the credibility and reproducibility of RWE studies. While there is universal agreement on the critical importance of …

Campbell’s Law Explains the Replication Crisis: Pre-Registration Badges Are History Repeating

Campbell’s Law explains the replication crisis. In brief, useful tools such as hypotheses, p-values, and multi-study designs came to be viewed as indicators of strong science, and thus goals in and of themselves. Consequently, their use became …

Demystifying Open Science in health psychology and behavioral medicine: a practical guide to Registered Reports and Data Notes

Open Science practices are integral to increasing transparency, reproducibility, and accessibility of research in health psychology and behavioral medicine. Drives to facilitate Open Science practices are becoming increasingly evident in journal …

Enhancing Public Access to the Results of Research Supported by the Department of Health and Human Services: Proceedings of a Workshop—in Brief

The National Academies hosted a hybrid public workshop in Fall 2023, sponsored by the National Institutes of Health, to explore approaches that U.S. Department of Health and Human Services (HHS) agencies could consider as they develop or update …

Exploring regulatory flexibility to create novel incentives to optimize drug discovery

Efforts by governments, firms, and patients to deliver pioneering drugs for critical health needs face a challenge of diminishing efficiency in developing those medicines. While multi-sectoral collaborations involving firms, researchers, patients, …

Making Research Data Publicly Accessible: Estimates of Institutional & Researcher Expenses

Academic institutions have made significant investments to support public access to research data requirements, yet little to no data about these services, infrastructure, and costs currently exist or are widely shared. For public access to research …

Processes and Lessons Learned in Establishing the Palliative Care Research Cooperative’s Qualitative Data Repository in Serious Illness and Palliative Care

Data sharing is increasingly an expectation in health research since implementation of the National Institutes of Health Data Management and Sharing Policy. Qualitative studies are not exempt from this data sharing requirement. Recognizing this …

The O3 guidelines: open data, open code, and open infrastructure for sustainable curated scientific resources

Curated resources that support scientific research often go out of date or become inaccessible. This can happen for several reasons including lack of continuing funding, the departure of key personnel, or changes in institutional priorities. We …
JUST-OS